abstract |
The present invention relates to formulations of octreotide or a pharmaceutically acceptable salt thereof, wherein the formulation provides controlled release of a therapeutically effective amount of octreotide over at least about two months. Methods of treating acromegaly, administering a reduction of growth hormone, methods of reducing IGF-1, and treating conditions associated with carcinoid tumors and VIP-secreting tumors are provided by administering a controlled release of octreotide. |